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PIM KINASES ARE REQUIRED FOR SHORT LIVED PLASMA CELL RESPONSES BY 
MURINE B CELLS 
John F Treml 
Michael P Cancro 
Humoral immunity is characterized by an early primary response of short lived plasma 
cells (SLPCs) secreting low affinity antibody followed by the formation of germinal center 
(GC) reactions and subsequent production of high affinity, class switched antibodies by 
long lived plasma cells (LLPCs). The lineage relationship between these two processes is 
not well established. We report that the SLPC element of the humoral response is Pim-
dependent. Pim-deficient animals have decreased numbers of PreB cells in the bone 
marrow, but other subsets remain comparable to control animals. In the periphery, only 
peritoneal B1a B cell numbers are deficient, contributing to low serum Immunoglobulin 
(Ig) and a lack of natural antibody. Other aspects of the primary B cell pool and splenic 
architecture reflect normal development. Following immunization, Pim1-/-Pim2-/- animals 
mount humoral immune responses deficient in the production of SLPCs. T-independent 
type II responses, comprised entirely of SLPCs, are virtually absent.   T-dependent 
responses are similarly compromised in their production of SLPCs, but do generate 
germinal center reactions leading to LLPC production. These deficiencies evince two 
distinct humoral immune responses: the Pim1/2-dependent early production of SLPCs, 
and the later, Pim1/2-independent, GC / LLPC response. The upstream mediators of 
these pathways correlate with the expression of TACI on SLPCs and BR3 on GCs / 
LLPCs, two receptors for the BLyS family of survival factors, known to be vital to B cell 
survival. 
 
 
	   v	  
Table of Contents 
                  Page 
Dedication         ii 
Acknowledgement        iii 
Abstract         iv 
Table of Contents        vi 
List of Tables         viii 
List of Figures         ix 
I. Introduction        1 
A. Overview       1 
B. B cells and humoral immunity     6 
II. Materials and Methods       8 
III. Development and homeostasis of pre-immune B cell pools   10 
A. Primary B cell development 10 
B. Primary B cell selection and homeostasis are coupled processes 11 
IV. The BCR and BLyS Receptors   	   	   	   	   12 
A. The B Cell antigen receptor     12 
B. The BLyS family of cytokines and receptors   13 
i. BLyS family ligands     14 
a. APRIL      14 
b. BLyS      15 
ii. BLyS family receptors 15 
a. BCMA 16 
	   vi	  
b. TACI 16 
c. BR3/BAFFr 17 
C. BLyS Receptor expression and physiology in developing and primary B 
cells 18 
V. Antigen experience and B cell subsets 20 
A. The generation and identity of antigen experienced  
B cell subsets 20 
B. T-independent B cell activation 23 
C. T-dependent B cell activation and the germinal center reaction 24 
D. Antigen experienced cell populations: SLPCs, LLPCs, and 
 memory B cells       25 
VI. The Pim family kinases       28 
A. Pim kinases and cell cycle regulation    28 
B. Pim kinase signaling and BLyS-mediated survival 29 
C. Pim kinase and the SLPC fate decision 30 
VII. Results 31 
A. Pim1-/-Pim2-/- mice have little serum immunoglobulin 31 
B. Primary B cell pools develop normally in Pim1-/-Pim2-/- mice 33 
C. TI-2 responses require Pim kinases 39 
D. TI-1 responses require Pim kinases 42 
E. TD responses are reduced in animals lacking Pim kinases 43 
	   vii	  
F. TACI is required for Pim kinase regulation by BLyS/APRIL 51 
VIII. Discussion 55 
Literature Cited 63 
	   viii	  
List of Tables 
                   Page 
1. Characteristics	  of	  Antigen	  Experienced	  Subsets	   	   	   	   	   22 
2. Characteristics	  of	  Primary	  B	  Cell	  Subsets	  and	  their	  Progenitors	   	   	   27	  
 
 
	   ix	  
List of Figures 
                  Page 
1. Receptor Expression and Cytokine Dependency.    5 
2. The humoral immune response      7 
3. Resting phenotype of Pim1-/-Pim2-/- animals     32 
4. Absolute numbers of B cell progenitor populations in Pim1-/-2-/- animals  34 
5. Splenic B cell subsets of Pim1-/-Pim2-/- animals    35 
6. Pim1-/-Pim2-/- animals have normal proportions and numbers of splenic  36 
B1 B cells 
7. Pim1-/-Pim2-/- animals lack peritoneal B1a but not B1b B cells   37 
8. Pim1-/-Pim2-/- animals have reduced serum immunoglobulin   38 
9. Pim1-/-Pim2-/- animals have no detectible natural antibody   39 
10. Pim1-/-Pim2-/- B cells are deficient in generating AFCs following   40 
TI-2 challenge 
11. Pim1-/-Pim2-/- B cells are deficient in generating antigen-specific antibody  41 
following TI-2 challenge 
12. Pim1-/-Pim2-/- animals have a limited response to TD antigen at d7 following 43 
immunization with NP-CGG 
13. Pim1-/-Pim2-/- animals make limited antigen-specific antibody at d7 following 44 
immunization with NP-CGG 
	   x	  
14. Pim1-/-Pim2-/- animals generate germinal centers following TD challenge 45 
15. Pim1-/-Pim2-/- animals generate germinal centers with normal architecture 46 
16. Pim1-/-Pim2-/- animals generate germinal centers at d10 post NP-CGG 47 
17. Pim1-/-Pim2-/- animals generation of germinal centers cells   48 
18. Low affinity SLPC responses in Pim1-/-Pim2-/- animals peak at d7  49 
19. Pim1-/-Pim2-/- have high affinity AFCs at d14     50 
20. Pim1-/-Pim2-/- generate high affinity, class switched antibody by d14  51 
21. TACI signaling up-regulates Pim1 message in B cells   53 
22. TACI, but not BR3, signaling up-regulates Pim1 message in B cells  54 
23. Model of short-lived plasma cell response     61 
 
	   1	  
 
I.  Introduction 
A. Overview 
 B lymphocytes are the effectors of humoral immunity, providing defense from 
pathogens through antibody production.  The induction of a humoral immune response 
involves the selective activation of antigen-specific B cells from previously established 
pre-immune pool.  Each cell in this quiescent population expresses a B cell antigen 
receptor (BCR) with a unique specificity.  When antigens cross-link surface-expressed 
BCR molecules, intracellular cross-phosphorylation signals are generated that lead to 
activation and differentiation, culminating in the formation of antibody-forming plasma 
cells and memory B cells.  These antigen-experienced populations maintain protective 
antibody levels and contribute to anamnestic responses upon subsequent antigen 
challenges.  Accordingly, an effective humoral immune system relies on the maintenance 
of pre-immune pools that are large enough to contain a broad array of BCR specificities 
and provide adequate surveillance given the organism’s size; as well as upon the 
generation and accumulation of memory and plasma cell compartments to sustain 
protective immunity.    
 Our understanding of how the sizes, compositions, and behaviors of these 
related but independent pools are regulated has advanced substantially in the last 
decade, as appreciation for the molecular systems involved has grown.   A central 
feature of current thought is that the establishment and maintenance of B cell pools relies 
on integrated signals from both the (BCR) and members of the B Lymphocyte Stimulator 
(BLyS, also termed BAFF) family of cytokines and receptors (1-3).  In these processes, 
the BCR provides specificity-based cues that determine the likelihood of successful 
maturation, activation, differentiation, and triage into various functional subsets (4). 
Proper assembly, expression and signaling of the BCR are central to B cell development 
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and survival. Any mutation that inhibits these functions results in a developmental block 
or shortened lifespan of the resulting cells (5, 6). In contrast, signals via BLyS family 
molecules directly mediate survival, determining the proportion of newly formed B cells 
that survive to enter mature pre-immune pools, the lifespan of these mature primary B 
cells, and the actions of antigen-experienced B cell subsets (Figure 1).  Like the pre-
immune pool, activated B cell subsets are also thought to have their survival regulated by 
BLyS family cytokines. In order to distinguish activated B cell pools from the pre-immune 
pool, a model has emerged where receptor expression, cellular localization and micro-
environmental cytokine concentrations effectively manage multiple subsets of cells using 
only two cytokines and three receptors(7). 
 The BLyS family is a recent addition to the tumor necrosis factor (TNF) 
superfamily of biomolecules.  It includes at least two ligands:  BLyS itself and a "sister" 
cytokine named A Proliferation Inducing Ligand (APRIL); as well as three receptors, 
BLyS receptor 3 (BR3, also termed BAFF-R), Transmembrane Activator and Calcium-
signaling modulating and cyclophilin ligand (CAML) Interactor (TACI), and B Cell 
Maturation Antigen (BCMA).  As with most TNF superfamily members, receptor ligation 
initiates interactions with one or more of the TNF receptor associated factors (TRAFs) (8, 
9), leading to downstream signaling cascades that can modulate survival and 
differentiation (10).  BLyS can interact with all three receptors; whereas APRIL binds 
BCMA and TACI, but not BR3.   The distinct TRAF interactions of the three receptors, 
coupled with their dissimilar ligand binding capacities and differential expression patterns, 
yields a broad range of combinations and thus affords independent regulation of various 
B cell subsets.  For example, antigen-experienced B cells, such as memory B cells and 
long-lived bone marrow (BM) plasma cells, express different BLyS receptors than pre-
immune B cells.  Moreover, BLyS ligands may oligomerize or localize within specific 
anatomic compartments, fostering unique interactions or limiting trophic support to 
particular anatomic niches.  Herein is a discussion of the nature, structure, and 
expression of BLyS family cytokines and receptors; followed by an in-depth discussion 
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their actions and signaling characteristics in the context of B lymphocyte development, 
survival, and activation.   Once activated, BLyS receptor expression changes as cells are 
sorted into new niches. Once these fate decisions are made, survival may be mediated 
by new cytokine  / receptor interactions. 
 Amongst the downstream mediators of BLyS signals are the Pim kinases. The 
Pim family of protein kinases are signaling molecules associated with B cell survival and 
proliferation. These kinases were originally described as proto-oncogenes activated by 
retroviral insertion resulting in aberrant overexpression. Molecular evidence has emerged 
linking Pims to specific phosphorylation events associated with cell cycle checkpoint 
events and expression of anti-apoptotic proteins. Despite these associations, animals 
lacking Pim kinases have been reported to have minimal immune phenotypes. 
 Contrary to the previously published work suggesting a minimal role for Pim 
kinases in B lymphocyte biology, we have found a critical role for Pim kinases in several 
aspects of B cell biology.  First, animals lacking Pim kinases (referred to as PimDKO or 
Pim1-/-Pim2-/-) have significantly reduced Ig titers. To identify the source of this reduction, 
we have undertaken a complete analysis of the B cell phenotype. At steady state, most B 
cell subsets were normal, however we did find a reduction in the frequency and number 
of Pre B cells, particularly the large, cycling Pre B cells. While the B1 B cell defect may 
partially contribute to the reduced Ig titers in Pim-deficient animals, it does not explain the 
extent of isotypes affected. 
Amongst mature populations, only B1a B cells in the peritoneal cavity are 
missing. In accord with this phenotype, Pim-deficient animals lack the so-called” natural 
antibodies produced by these cells. All other mature populations (FO, MZ, splenic B1 and 
peritoneal B1b) appear in frequencies and absolute numbers comparable to control 
animals. 
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 Perhaps most significantly, when these animals are challenged with TI-1, TI-2 or 
TD immunogens, SLPC responses are drastically impaired. Despite this, GC and LLPC 
responses are reduced, but largely normal. These data indicate that Pim kinases are 
specifically required for the generation, maintenance or survival of SLPC cells, but not the 
adaptive elements of a humoral response. Because all SLPCs are affected by Pim 
deficiency independently of the stimulatory signals, we hypothesize that this phenotype is 
not mechanistically proximal to antigen-initiated signals, but results from some 
generalized feature of AFC generation, function or survival. Specifically, we propose a 
model where survival of SLPCs is dependent upon Pim expression induced by capture of 
BLyS or APRIL by TACI.  
 This dissertation explores these deficiencies and what they might reveal about B 
cell biology. Below is an introduction to humoral immunity as well as the generation of a 
pre-immune pool of B cells and how these pre-immune pools are activated by antigenic 
stimulation. Following that are discussions of the nature of the BCR and BLyS receptors 
and the roles they play in both pre-immune and antigen experienced B cells. Lastly, the 
role of Pim kinases in cell cycle and survival are introduced. In the results section, we 
present new findings linking the generation, function and survival of SLPCs made shortly 
after immunization to Pim kinases; and ultimately to the expression of the BLyS receptor, 
TACI. 
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Figure 1: Receptor Expression and Cytokine Dependence.  Naïve, mature B cells 
express both BR3 and TACI, however only BLyS is required for normal development.  
Stimuli result in changes in receptor expression with TD stimuli favoring BR3 expression 
and leading to germinal center reactions while TI stimuli favors TACI expression on short 
lived antigen producing cells.  Dependence on BLyS or APRIL specifically has not been 
fully demonstrated for recently stimulated cells. LLPCs express BCMA and require APRIL 
for normal development / survival.  Memory cells are known to express TACI, however 
they appear independent of either BLyS or APRIL. 
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B. B cells and Humoral Immunity 
 The humoral immune response is characterized by the production of antibodies 
with specific binding to an epitope present on the immunogen. Antibodies are soluble 
BCR proteins produced by plasma cells selected from a pre-immune pool of FO B cells 
that bore antigen receptors specific for the immunogen in question. The antigen-binding 
portion of the BCR / antibody is generated by random recombination and modulation of 
pre-existing germline elements in order to bind to a vast array of unknown (non-self) 
epitopes. The generation of this repertoire of preimmune cells is described below in 
section II. Antibody binding to these cognate epitopes serves several purposes including 
coating and sterically interfering with a pathogen or toxin’s function, facilitating 
phagocytosis or mediating cellular cytosis by complement.  
The activation of B cells to develop into antibody-secreting plasma cells can 
result from a variety of stimuli. Humoral immune responses can occur in cooperation with 
CD4+ T helper cells, a T-dependent response, or without T cell help, a T- independent 
response. In general, both responses begin in the first week after antigen exposure with 
the rapid proliferation of extrafollicular plasmablasts and the production of low affinity IgM 
antibodies. In T-dependent responses, this low affinity response is followed in the second 
week by the production of higher affinity antibody by plasma cells that have undergone 
expansion and selection during germinal center reactions (Figure 2.) Both of these 
responses are discussed in greater detail below, including their cytokine and survival 
requirements in sections IIIb and IIIc.  
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                     Time  
Figure 2: The humoral immune response. Short-lived plasma cells producing low 
affinity IgM are generated early in the immune response. Later, long-lived plasma cells 
producing high affinity, class-switched antibody and memory B cells are generated 
following germinal center reactions. 
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II.   Materials and Methods 
Mice C57BL/6 mice were purchased from The Jackson Laboratory and B6x129 mice 
purchased from Taconic Labs were used as controls for the Pim1-/-Pim2-/- mice. Animals 
were immunized with preparations of NP-CGG in Alum (50ug in 200ul PBS) or NP-Ficoll 
in Alum (50ug in 100ul or 200ul PBS), or NP-Ficoll with Fitc-LP910-50ug in 200ul PBS) 
injected ip.   TACI-/- animals were provided by Dr. Richard Bram (Mayo Clinic, Rochester, 
MN.) Pim1-/-Pim2-/- mice were provided by Dr. Casey Fox (The Jackson Laboratory, Bar 
Harbor, ME.) All animal husbandry and procedures were carried out in accordance with 
the Animal Welfare Act. 
Flow cytometry Spleen, bone marrow and peritoneal cells were surface stained with Abs 
that recognize B220 (clone RA3-6B2 BD Pharmingen,San Jose, CA), CD19 (clone 1D3, 
BD Pharmingen,San Jose, CA), Igκ (clone 187.1 Southern Biotech, Birmingham, AL), Igλ 
(clone JC5-1 Southern Biotech, Birmingham, AL), Igδ (clone 11-26c.2a BD Pharmingen, 
San Jose, CA) CD4 (clone H129.19 BD Pharmingen, San Jose, CA), CD8 (clone 53-6.7 
eBiosciences, San Diego, CA ), F4/80 (clone BM8 eBiosciences, San Diego, CA), GR1 
(clone RB6-8C5 eBiosciences, San Diego, CA) and CD23 (clone B3B4 BD Pharmingen, 
San Jose, CA), GL7 (clone 8C5 BD Pharmingen,San Jose, CA) CD95 (clone Jo2 70 BD 
Pharmingen, San Jose, CA), CD11b (M1/70 BD Pharmingen, San Jose, CA), CD93 
(clone AA4.1 eBioSciences, San Diego, CA), CD5 (clone 53-7.3 BD Pharmingen, San 
Jose, CA) and CD21 (clone 7G6, BD Pharmingen, San Jose, CA). Cells were analyzed 
using LSR II (BD Biosciences, San Jose, CA) and Flowjo software (Treestar, Ashland, 
OR.) 
B cell enrichment and culture assays B cells were enriched by positive selection using 
CD23+ MACS on Miltenyi columns as previously described (11). Resulting cell 
suspensions were 90%+ follicular B cells as verified by CD23 and IgM FACS. Cells were 
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enumerated after lysis of red blood cells and cultured in B cell media containing DMEM or 
RPMI 10% Characterized FBS (Thermo Scientific HyClone, Waltham, MA) Non-essential 
Amino Acids, L-Gluatamine, 2-Mercaptoethanol, OPI and gentamycin. Cells were 
cultured for indicated times in the presence of BLyS (Human Genome Sciences, 
Rockville, MD) or APRIL (Peprotech, Rocky Hill, NJ.) For qPCR, cells were harvested for 
mRNA by pelleting and extraction of mRNA using Qiashredder and RNeasy kits (Qiagen, 
Valencia, CA.)  
Quantitation of serum antibody and antibody secreting cells Serum antibody specific for 
NP was assayed by ELISA incubating serial dilutions of sera or control antibody on NP-
coated plates and detecting with IgM, lambda or IgG specific reagents, extravidin-HRP 
and tetramethylbenzidine substrate kit (BD PharMingen, San Jose, CA.) Concentrations 
of NP-Specific antibody were established by reference to a standard curve. The method 
for quantitating antibody secreting cells by ELISPOT has been described (12). Briefly, 
cells were recovered from spleen or bone marrow and enumerated. Serial dilutions of 
cells were plated on multiscreen HTS plates (Millipore, Billerica, MA) coated with NP, 
NP3 or NP33 coupled to the carrier BSA and incubated for 4 hrs at 37°C. Plates were 
washed 5x before adding biotinylated detection antibody (anti-lambda, anti IgG or anti-
IgM). Plates were incubated 1hr at RT and washed. SA-AP was added, incubated 1hr at 
RT, plates were washed and then given BCIP/NBT substrate (Sigma Aldrich, St. Louis, 
MO) and allowed to develop. Plates were dried and spots were enumerated using an 
ELISpot reader (CTL, Cleveland, OH) and analyzed with Immunospot software version 
3.2 (CTL, Cleveland, OH). 
Quantitative PCR Message RNA levels were established by qPCR using commercially 
inventoried primers in an ABI 7500 analyzer (Applied Biosystems, Foster City, CA.) 
Relative expression was determined by ddCT method according to manufacturer’s 
methods.  
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Immunohistochemistry  Splenic architecture was observed by microscopy on  Zeiss LSM 
510 Meta-confocal and Nikon E800 instruments. Spleen sections were harvested and 
frozen down in OCT under 2-methyl butane. Sections were cut at 5-8 micron thickness, 
fixed with acetone and stained with antibodies or PNA as indicated.  
 
III. Development and homeostasis of pre-immune B cell pools	  
A.   Primary B cell development  
 B cells are generated throughout life from stem cells in fetal liver, neonatal 
spleen, or adult bone marrow (BM).  Multi-potent cells arise from these progenitors and, 
upon initiation of lymphoid gene expression, yield B lineage precursors.  Excellent, highly 
detailed reviews of early B cell development are available elsewhere (13-17). Briefly, 
immunoglobulin heavy and light chain gene rearrangements occur as cells transit the BM 
pro- and pre-B stages respectively.  These genetic events culminate in the production of 
an immunoglobulin heavy/light chain pair that is assembled and, in conjunction with the 
Ig-alpha and Ig-beta signaling molecules, form a functional BCR that is transported to the 
cell surface.  BCR surface expression marks the progress into the Immature (IMM) BM 
subset.  These newly formed B cells continue their maturation after they migrate to the 
periphery, passing through several so-called transitional (TR) developmental stages 
before entrance into primary B cell pools.  Cells completing these differentiative 
processes enter one of the major pre-immune subsets: the follicular (FO) and marginal 
zone (MZ) populations.   
 
 
 
 
	   11	  
B.  Primary B cell selection and homeostasis are coupled processes  
 While details of primary B cell differentiation are extensively reviewed elsewhere 
(18, 19), a feature critical to the concepts discussed here is that stringent selection, 
based on BCR specificity, occurs within the IMM and TR pools.  This selection transpires 
at both the IMM and TR stages.  Indeed, only about 10% of the IMM cells generated live 
to exit the BM, and fewer than half of the resulting TR cells survive to finally join mature 
pre-immune B cell pools (20, 21). Both negative and positive selection events contribute 
to these cell losses.    
 Negative selection – the elimination of potentially autoreactive B cell clones – 
occurs at both the IMM and TR stages.  Current thought holds that elimination at the IMM 
stage is engendered by high avidity BCR engagement, whereas cells undergoing less 
avid but sustained BCR interactions persist into the TR stages, where they then die 
before maturation (22). Substantial evidence from transgenic mouse systems confirms 
that autoreactive clones are eliminated at both of these stages (23-25). More recently this 
has been confirmed in humans by studies that revealed similar selection against 
autoreactive BCR specificities during TR maturation (26). Moreover, these cell losses 
failed to occur in autoimmune patients (27). 
 Positive selection – the preferential survival of clones whose receptors meet 
minimum so-called "tonic" BCR signaling requirements - occurs at these stages as well, 
particularly among TR cells (28-31). Moreover, mature primary B cells continue to require 
continuous sub-threshold BCR signals for survival, since conditional ablation of either the 
BCR itself or proximal BCR signaling components leads to the rapid death of most 
mature B cells (6). The requirement for persistent, low-level BCR signaling is consistent 
with the observation that BCR engagement has a clear positive effect in cellular survival 
at the BM / periphery interface and beyond (32). The consequence of this effect is best 
illustrated in mixed bone marrow chimeras, where the mature B cell pool is derived from 
differing mixtures of BCR transgenic or other genetically manipulated B lineage 
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progenitors (33-36). These experiments show a distinct connection between BCR 
specificity and selection in conditions of interclonal competition.    
An overarching conclusion arising from such experiments is that in the TR 
subsets and beyond, BCR specificity determines a cell’s relative fitness to capture or 
utilize limited trophic resources for survival (34, 35). This in turn suggests that while a 
range of tonic BCR signaling can afford survival, those cells with optimal tonic BCR 
signaling levels will be more likely to survive to maturity and will persist longer in per-
immune pools.  Considered together, these concepts unify specificity-based selective 
processes with homeostatic control, because B cell production rate and lifespan are the 
determinants of the primary pool’s size.  Further, the prediction that limiting trophic 
factor(s) would be the basis for homeostatic control foreshadowed the discovery of BLyS 
as the biological metric for “space” in primary B cell compartments. 
 
IV.    The BCR and BLyS Receptors   
 As discussed above, B cell development is controlled by signaling from two key 
surface receptors, the BCR and the BLyS family receptors. Accordingly, an overview of 
these receptors and their ligands follows. TABLE 2 lists pre-immune B cell subsets and 
their surface phenotypes, their BCR and BLyS receptor expression and BLyS ligand 
dependence 
A. The B Cell antigen receptor 
 B cell development is defined by the expression and functionality of membrane 
bound BCR molecules. The BCR is comprised of a pair of light chain molecules 
associated with a pair of either µ or δ membrane-spanning heavy chains, non-covalently 
linked to Igα and Igβ elements that bear the intracellular signaling elements. In a pre B 
cell, the light chains of the preBCR are comprised of lambda5 and VpreB. In the mature 
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BCR, light chains may be either kappa or lambda. In the mouse only 5% of peripheral 
CD19+ B cells express lambda. 
Prior to the Pre B cell stage, no BCR is expressed, however genomic 
rearragement of the immunoglobulin genes are active as early as the common lymphoid 
progenitor stage (37). At the Pre B cell stage cells express a PreBCR comprised of a 
successfully recombined heavy chain paired with the surrogate light chain elements 
lambda5 and VPreB. One explanation of this pairing is proposed to be a check on the 
structural stability of the recently formed heavy chain and an opportunity for successful 
heavy chains to proliferate as large Pre B cells prior to additional immunoglobulin 
rearrangement and pairing with light chains (38). In this way these successful heavy 
chains can be paired with a variety of light chains thus hedging against the loss of cells 
due to unsuccessful light chain rearrangements.  
 Once a light chain is made that can productively pair with the heavy chain, 
mature BCR proteins are expressed on the surface of immature B cells in the bone 
marrow. Immature B cells then leave the bone marrow to complete their development in 
the periphery as transitional B cells. B cell development is discussed in greater detail 
below in section III.  
 How signaling from the PreBCR and BCR occurs has been a topic of great 
interest. Since each BCR bears a receptor of unique specificity, the notion of ligand 
mediated signaling becomes difficult to fathom. However, without a ligand, there is 
nothing to crosslink BCRs together to allow cross-phosphorylation of signaling elements. 
The concept of ‘tonic signaling’ has emerged following experiments that demonstrated 
singaling from BCRs lacking some, or all, extracellular elements (39-42). 
B. The BLyS family of cytokines and receptors 
Most members of the BLyS family were discovered through genomic homology 
searches (43-45).  As some family members were discovered simultaneously by several 
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laboratories, they possess multiple names and acronyms. Throughout this dissertation, 
the two ligands are refered to as APRIL and BLyS; and use the terms BCMA, TACI, and 
BR3 for the three receptors.  The following two sections discuss the biochemical 
characteristics of BLyS subfamily ligands and receptors respectively. 
i. BLyS family ligands 
There are two ligands in the BLyS family: BLyS and APRIL.  Both cytokines are 
TNF family receptors expressed by a variety of cell types, particularly among leukocytes.  
Both are initially synthesized as membrane-spanning monomers, but associate as trimers 
and are cleaved to soluble form by furin.  Although they share homology with other TNF 
ligands, BLyS and APRIL are smaller than most - consisting of only transmembrane 
domains, a Furin-cleavage site and a TNF homology domain.  In addition, receptor 
binding face structure and amino acid composition also distinguish these ligands from 
other superfamily members (46). 
 
a. APRIL  
APRIL was isolated based on mRNA expression in cell lines, and so-named 
because it could provoke proliferation in transfected fibroblasts (47). APRIL can interact 
with BCMA and TACI, but not with BR3.  APRIL also bears an N-terminal region that 
interacts with surface proteoglycans through a short sequence of basic residues (48-51). 
The exact biological role(s) of this feature is not yet clear, but may be to facilitate binding 
of APRIL to TACI, BCMA or other receptors by generating higher order complexes (49). 
Because APRIL knockouts lack a profound phenotype, the biological functions of 
APRIL are only now being explored in detail.  Given their overlapping receptor binding 
specificities, many functions of APRIL may prove redundant with those of BLyS, at least 
to the extent that unique attributes may be difficult to discern unless studied in the 
absence of BLyS (52-55). Nevertheless, APRIL clearly plays a modulatory role in certain 
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aspects of B cell activation and isotype switching (56, 57); and likely interacts with bone 
marrow plasma cells via BCMA (58, 59).  Indeed, while expressed in a variety of tissues, 
APRIL message is seen at very high levels in both human (60) and mouse osteoclasts.  
The expression of this cytokine in bone may thus be vital to the support of long–lived 
plasma cells (LLPCs), as LLPCs reside in the bone marrow and are reduced in mice 
lacking BCMA (61). Dendritic cells were recently reported to secrete APRIL constitutively 
and this production is increased following stimulation of these cells with TLR ligands (62). 
Finally, APRIL fosters the viability or progression of some cancers (63-66).   
b. BLyS 
Sequence searches also contributed to the discovery of BLyS, and the features 
of this cytokine were reported simultaneously by several groups (43-45, 67). BLyS can 
interact with Magnesium, and has an exceptionally deep and acidic cleft that in part 
explains its unique affinity for the comparatively basic BR3 receptor, as well as its lower 
affinity for TACI and BCMA when compared to APRIL.   
BLyS is produced by a wide variety of cell types, including neutrophils, dendritic cells, 
monocytes, macrophages, and others (68). BLyS message and furin-mediated release is 
up-regulated by some cytokines, including interferon gamma and IL10 (69). The furin-
cleaved, soluble trimeric form is the primary effector of in vivo function, but BLyS can also 
exist as a 60-mers whose spectrum of receptor binding activities are expanded, 
especially with TACI (70). Finally, heterotrimers of BLyS and APRIL exist, although their 
significance remains poorly explored (71). 
  ii.    BLyS family receptors 
There are three receptors for BLyS and/or APRIL:  BCMA (72), TACI (73), and 
BR3, the product of the previously defined bcmd locus (Bcmd/BR3) (1, 74-78). The basic 
features of these receptors are summarized here.  More detailed considerations of the 
	   16	  
ligand binding motifs, as well as descriptions of key contact residues and structural 
organization of each receptor, have been reviewed (51). 
a. BCMA 
BCMA is a 20 kDa Type III transmembrane protein that was originally identified in 
a human T cell lymphoma (72, 79). BCMA can bind both BLyS and APRIL, but the 
considerably higher affinity for APRIL suggests this may be the most relevant ligand in 
vivo.  Structurally, BCMA has the least homology to other TNF receptor family members.  
Like BR3, BCMA contains a single characteristic CRD motif.  Indeed, among the TNF 
family of receptors, only BCMA and BR3 exhibit this feature.  BCMA can interact with 
TRAFs-1, 2 and 3; and downstream effects include activation of NF-kB transcriptional 
mediators and JNK kinases (80). 
The role played by BCMA in B cell biology remains somewhat enigmatic.  BCMA 
is expressed in neither developing nor primary B cells, and BCMA knockout mice show 
no phenotypic abnormalities within the pre-immune B cell compartments.  Further, the 
abnormalities seen in the primary B cell pools of other BLyS receptor knockouts are 
BCMA independent.  More recently, BCMA expression has been confirmed on LLPC 
populations, and detailed studies of BCMA knockouts support a role for the generation 
and maintenance of these cells.    
b. TACI 
TACI is a 293 amino acid Type III transmembrane protein that was initially 
identified based on its ability to interact with CAML (80). Similar to BCMA, TACI can bind 
both BLyS and APRIL but, unlike BCMA, TACI binds each with similar affinities (81). 
Structurally, TACI bears two CRDs, and has cytoplasmic domains capable of interacting 
with TRAF 2, 5, and 6.  Receptor ligation activates a variety of downstream transcriptional 
regulatory pathways, including NFAT, AP-1 and the classical NF-kB pathway, presumably 
through a CAML-independent mechanism (73). Signaling through TACI has been shown 
	   17	  
in numerous experimental and transformed cell types to result in the classical NF-kB 
mediated upregulation of the X-linked Inhibitor of Apoptosis Protein (XIAP), but not bcl2 
family members (82). 
TACI expression is restricted to B cells and a subset of activated T cells.  
Although TACI can bind both BLyS and APRIL with comparatively strong affinity, the 
biological effects of TACI ligation remain unclear and somewhat controversial.  Early 
results from TACI knockout mice suggested a negative role for TACI (83), because these 
animals exhibited B cell hyperplasia and humoral autoimmune symptoms including 
glomerulonephritis, proteinuria and anti-dsDNA antibodies.  More recently, there has been 
accumulating evidence that TACI is a positive regulator of B cell survival. For example, 
APRIL stimulation of primary B cells ex vivo, which should engage only TACI, improves 
survival (84). Further evidence for positive regulatory roles in survival or differentiation 
stems from findings that show TACI facilitates isotype switch recombination, particularly to 
gut-associated IgA isoforms (85, 86). It is unclear whether this dichotomy reflects 
opposing roles for TACI in different cellular and anatomic contexts, or instead indicates 
that the B cell hyperplastic phenotype in knockouts is a secondary phenomenon.     
c. BR3/BAFFr 
BR3 is the most recent addition to the BLyS family receptors.  Its discovery 
resulted from results suggesting that neither TACI nor BCMA dramatically influenced B 
cell activities, implying the existence of an additional BLyS-binding receptor.  Similar to the 
discovery of BLyS, BR3 was reported simultaneously by several groups (80).  Importantly, 
it proved to be the gene product of a locus that had previously been shown to govern late 
primary B cell differentiation and mature B cell survival (76). BR3-BLyS interactions have 
proven critical to the maintenance of primary B cells, as shown clearly in knockout and 
mutant mice (77, 87). Structurally, BR3 contains one extracellular CRD that interacts with 
ligand and a single intracellular recognition site for TRAF3.  Recent evidence suggests 
that BR3-mediated interactions with TRAF3 initiate and sustaining downstream signaling 
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(8). These signaling targets include non-classical NF-kB pathway activation and 
subsequent upregulation of multiple Bcl-2 family members (detailed below).  This strategy 
contrasts the survival genes regulated by TACI, in that Bcl-2 family members inhibit 
apoptosis upstream of the mitochondria.  
C.  BLyS receptor expression and physiology in developing and primary B cells 
Extensive evidence links signals via BLyS receptors, particularly BR3, with the 
survival of TR, FO and MZ B cells.  Indeed, BR3 and TACI are first expressed among 
IMM B cells in the bone marrow, and their expression continues to increase as cells 
transit through TR stages.  Within pre-immune FO and MZ pools, BR3 and TACI reach 
relatively high and constant levels (88).  MZ B cells are highly sensitive to conditions 
when BLS is limiting, likely related the uniformly high levels of TACI and BR3 expressed 
(78, 89). 
BLyS signaling through BR3 is crucial for the survival of all pre-immune B cell 
subsets from the TR stage onward.  This was initially evidenced by the profound mature 
B cell deficiency in the A/WySnJ mouse (74-77, 90, 91), a feature that segregated as a 
single autosomal trait reflecting a 400bp insertion in the intracellular tail of BR3 (78). This 
and subsequent studies have led to the notion that BLyS signaling via BR3 controls the 
size and composition of pre-immune B cell pools (reviewed in (92)). For example, either 
ectopic BLyS expression or exogenous BLyS administration yields B cell hyperplasia and 
humoral autoimmune manifestations (44, 88, 93).  Conversely, both BLyS and BR3 
knockout mice display primary B cell deficiencies reminiscent of the A/WySnJ (77, 87). 
Thus, the BLyS/BR3 axis is central to the homeostatic control of primary B cell 
numbers, with current thought favoring the notion that available BLyS levels determine 
both the proportion of TR cells that survive to enter the mature pools and the lifespan of 
mature B cells themselves (see (94) for reviews).  By controlling the entry rate and 
lifespan of mature B cells, a set-point for steady-state numbers is thus imposed, whereby 
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BLyS availability constitutes the “limiting resource” for which cells in these primary pools 
compete.  This prompts a conceptual model whereby TR, FO, and MZ B cells 
continuously compete for BLyS consumption (binding), such that when consumption and 
availability are balanced, the set-point for steady state numbers is achieved (92). 
The ability to vary the survival of TR B cells has obvious implications regarding 
negative selection, since it implies that the thresholds for negative and positive selection 
at the TR stage may vary, based on available BLyS and the tonic BCR signaling 
capabilities within the competing cohort of emerging cells.  Recent studies in several 
transgenic systems verify this plasticity in TR selection stringency (95-97), showing that 
when BLyS is non-limiting, self-reactive clonotypes that normally die at the TR stage 
instead survive and mature.  Importantly, BLyS over expression does not rescue cells 
deleted at the IMM stages, suggesting that a developmental switch affords the ability for 
BR3 and BCR to cross-regulate one another’s signaling outcomes.  This may reflect the 
onset of BLyS receptor expression per se, but a growing literature suggest that 
differentiation-dependent changes in intracellular signaling systems that afford cross-talk 
between the BCR and BR3 may also play a role (42, 98-101). 
An extension of this model of BLyS-mediated homeostasis can be used to 
understand how the same cytokines and receptors are utilized to maintain the survival of 
antigen experienced B cell subsets. As described above in section III D, SLPCs, GCs, 
LLPCs and memory B cells all have subset-specific BLyS receptor expression patterns 
and many of these cells also have well defined physiological niches (GC cells exist in the 
PALS/follicle interface, LLPCs often reside in the BM in contact with osteoclasts, SLPCs 
thrive in the splenic red pulp as extrafollicular foci.) In combination, these characteristics 
may allow for a shift in survival signals from BLyS:BR3 interactions to other 
combinations. 
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V.   Antigen experience and B cell activation  
A.  The generation and identity of antigen experienced B cell subsets 
The clonal daughters of naïve B cells recruited into immune responses comprise 
antigen-experienced subsets.  These are summarized in Table 1 and include the 
responding B cells at various stages of activation, as well as antibody-forming cells 
(AFCs) and memory cells.  B cell responses are generally categorized as either TD or TI, 
depending on whether cognate T cell help is involved in initiating the response.  TD 
responses arise from FO B cells and are elicited by protein antigens.  Following receptor 
ligation and internalization, such antigens can be processed to short peptides that are 
complexed with and presented in the context of MHC class II molecules, facilitating T cell 
costimulation.  A distinguishing feature of TD responses is the germinal center (GC) 
reaction, in which B cells undergo class switch recombination and somatic 
hypermutation, as well as the specificity-based selection that underlies affinity maturation.  
Descendants of cells in the GC reaction include LLPCs that home to and reside in the 
bone marrow; as well as memory B cells, whose exact homing and localization 
characteristics remain less clear.   In contrast, TI responses do not involve T cell help and 
do not yield a GC reaction.  Accordingly, they lack affinity maturation, do not yield long-
lived plasma cells, and produce little if any humoral memory.  Two types of TI antigens 
exist: TI-1 antigens induce proliferation and differentiation through the stimulation of 
pattern recognition receptors such as Toll like receptors (TLRs); whereas TI-2 antigens 
bear densely repeating epitopes, and are thought to yield activation via exceptionally 
strong and sustained BCR cross-linking.  
Reflecting these two major modes of activation, the participation and chronologic 
appearance of antigen-experienced subsets follow two general patterns.  Both TD and TI 
responses yield an initial proliferative burst among the activated primary B cell clones that 
have localized to extrafollicular foci in the splenic red pulp.  These rapidly expanding cells 
quickly give rise to short-lived plasma cells (SLPCs), which generate the initial low affinity 
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IgM antibodies observed during early primary responses, and in some cases modest 
amounts of some IgG subclasses.  Following these events, most TI responses dissipate 
within an 8 to 14 day course.   
During TD responses, the early generation of LLPCs is paralleled by the initiation 
of a GC reaction.  Within the GC, two populations emerge:  one that is rapidly 
proliferating and one that is less mitotically active.  These are polarized within the GC, 
and corresponded to the historically named “dark zone” and “light zone” respectively.  
Class Switch Recombination and Somatic hypermutation (SHM) are initiated in the GC, 
following by the upregulation of enzymatic machinery associated with these processes.  
In toto, these events result in the generation of B cells that have switched heavy chain Ig 
isotypes, and that have accumulated point mutations in their BCR combining site.  Those 
daughter clones bearing novel specificities generated by SHM then undergo selection 
against either low antigen affinity or self-reactivity, and positive selection for higher 
affinity.  The mechanisms underlying this selection remain debated, as do the 
compartmentalization and trafficking patterns of cells in the GC (102-104). Regardless of 
exact mechanism, cells surviving GC selection give rise to LLPC that migrate to and 
reside in the BM, and to memory B cells.  While the phenotypic characteristics of these 
cells remain debated, their respective roles in immunity are well documented (105-107). 
The LLPCs provide ongoing protection from reinfection through continuous high affinity 
antibody secretion, and are the source of standing antibody titers associated with 
protective adaptive immunity.  Memory B cells provide a long-lived population of 
expanded, antigen specific cells that are quickly activated upon subsequent antigen 
encounters, affording the rapid response time associated with anamnestic responses.   
Additionally, antigen activation, including those delivered through BCR, TLRs, or 
CD40 engagement, engender characteristic BLyS receptor profiles.  Because of the 
different ligand preferences for each BLyS family receptor, as well as their disparate 
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signaling outcomes, acquiring novel BLyS receptor profiles will specify independent or 
overlapping homeostatic niches (108, 109). 
 
Table 1:  Characteristics of Antigen Experienced Subsets 
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Surface 
Phenotype 
BLyS 
Receptors 
BLyS Ligand 
Dependence 
    
T-
In
de
pe
nd
en
t 
R
es
po
ns
es
 
Early 
AFC/SLPC  B220
loCD19+/-
sIg+/-icIghi BR3, TACI ? 
Early 
AFC/SLPC  
B220loCD19+/-
sIg+/-icIghi BR3, TACI ? 
 
B220+CD19+ 
GL7+ 
BR3, 
TACI 
 
GC formation 
ensues but 
smaller and 
less persistent 
in BLyS or 
BR3 deficiency 
GC 
    
 B220losIg-icIg+ BCMA BLyS or APRIL 
LLPC 
    
Memory  
B220+sIG+ 
IgD- 
TACI? None? 
T-
D
ep
en
de
nt
 R
es
po
ns
es
 
     
Peritoneal 
B1a  and 
B1b 
 CD43
+CD23-
CD5+/- TACI? 
None 
described 
N
at
ur
al
 
A
nt
ib
od
ie
s 
     
 
 
	   23	  
B.   T-Independent B cell activation  
Following encounter with TI-1-stimulating TLR agonists, B cells dramatically up-
regulate TACI (84). A similar finding occurs following stimulation with TI-2 antigens, 
where TACI expression increases the number of AFCs generated (110). The role played 
by TACI in these rapidly dividing but relatively short lived responses remains puzzling, 
but recent findings have suggested it is involved in controlling entry and exit from cell 
cycle (110). A potential role for BLyS in cell cycle entry and success has been posited, 
although the receptor involved was not clear from these studies (111). TACI may be 
directly promoting survival of short-lived AFCs, particularly when bound by multimeric 
ligand arrays such as those afforded by oligomerized BLyS or surface bound APRIL (70). 
SLPCs generated during either TI or TD responses also express high levels of TACI, in 
contrast to the phenotype of LLPCS (see below) which instead up-regulate BCMA.  The 
difference in which receptor is up-regulated in each response may be key to the 
difference in lifespan. 
Information is sparse regarding the signaling systems and downstream targets of 
TACI in B cells activated by TI antigens.  Nonetheless, these likely involve the activation 
of classical NF-kB signals; and in contrast to the pre-mitochondrial survival mechanisms 
afforded by BR3 signals, post-mitochondrial anti-apoptoic mechanisms, including stress 
response proteins such as XIAP, may be involved (82).  Since such mechanisms are 
effective in preventing apoptosis engendered by cell cycle checkpoint failures or unfolded 
protein responses, these pro-survival mediators might be expected for B cells undergoing 
extensive division and differentiation to high levels of Ig protein production (112). 
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C.   T-dependent B cell activation and germinal center reaction 
The striking parallels between GC and primary B cell differentiation, in terms of 
negative and positive selection processes based on BCR specificity, suggest 
mechanistically similar processes.  Substantial evidence suggests that members of the 
BLyS family may indeed play a role in the establishment and proper evolution of the GC 
reaction, but the members involved and mechanisms of action remain cloudy.  In general, 
BCR engagement per se, as well as with concomitant CD40 ligation, leads to a BLyS 
receptor signature in which BR3 is up-regulated (32). Alternatively, Qian et all showed 
that Act 1 functions as a negative regulator of both BR3 and CD40, suggesting potential 
cross talk and cross-modulation between different TNF family receptors expressed in the 
GC (113).TACI is elevated following TD stimulation as well, although not to the extent 
seen with TI antigens.  Interestingly, GC B cells retain this phenotype, suggesting that the 
BLyS-BR3 interactions may play a role in this aspect of TD responses.  However, early 
studies in the BR3 mutant A/WySnJ mouse strain suggested GCs likely form, since TD 
memory could be generated - albeit with reduced efficacy and less extensive isotype 
switching (75). In agreement with this, more recent work from the Manser laboratory 
showed that BR3 is not required for the generation of GCs (114), but  plays a role in the 
appropriate evolution of the overall GC reaction.  This finding was extended in studies 
that used soluble BCMA-Fc to block both APRIL and BLyS, yielding the same results 
(114, 115).  Thus, while not profoundly affected, GCs generated in the absence of 
appropriate BLyS or BR3 signaling are small, transient and fewer in number.  In addition 
to possible B cell intrinsic activities for BLyS in the GC reaction, follicular dendritic cells 
(FDC) networks do not mature in GCs when BLyS and APRIL are blocked (116). This 
may reflect a loss of FDC supporting signals secondary to the decreased number of B 
cells in the GC, although the exact basis remains speculative.   
The potential roles of BLyS family members in the selective processes that follow SHM 
within GCs have not been directly interrogated.  This in part reflects the complexity 
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associated with blocking BLyS-mediated signals necessary for primary cell survival, as 
any effects on GC selection might indirectly result from a reduction in primary B cells that 
seed the GC.  In addition, analysis of negative and positive B cell selection in the GC 
requires single cell analyses, exacerbating the difficulty of this problem.  
D.    Antigen experienced cell populations: SLPCs, LLPCs and memory B cells 
The BLyS receptor expression profiles and cytokine requirements for LLPC and 
MEM cells appear to be unique.  Recent evidence supports a role for BCMA in 
maintaining LLPC survival (61). As might be expected, these cells are sensitive to only 
combined withdrawal of BLyS and APRIL, and some are apparently independent of both 
cytokines.  The ability of at least some LLPCs to use APRIL as a survival factor is 
intriguing, since osteoclasts generate large amounts of this cytokine, and might thus 
provide localized high levels of APRIL in specialized bone marrow niches.   Further, 
APRIL exhibits the unique ability to bind proteoglycans (49), which are abundantly 
expressed on resident BM accessory cells where long-lived PCs co-exist.  The 
downstream effects of BCMA signaling in LLPCS are not yet extensively characterized, 
as these are rare populations of B cells that are difficult to maintain in vitro.  However, B 
cell and plasma cell lines reveal classical NF-kB activation, the upregulation of a number 
of proteins associated with antigen presentation and co-stimulation, and increased IL-2 
production following BCMA ligation (117). 
In contrast to LLPCs, memory B cells express elevated levels of TACI, at least 
early in their generation (59). Despite this, most evidence points to a lack of reliance on 
either BLyS or APRIL when both cytokines were neutralized using sufficient soluble 
TACI-Ig to ablate naïve B cells (59). Further supporting BLyS independence, anti-BLyS 
antibody failed to eliminate B cell memory in a variety of experiments designed to elicit 
memory B cell generation (118). 
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SLPCs are the first plasma cells generated in response to antigenic challenge. 
These cells rapidly migrate out of the follicle and into the red pulp of the spleen. The 
migration of these cells from the follicle has been attributed to the downregulation of the 
chemokine receptor CXCR5 and the upregulation of CXCR4. Cells then migrate towards 
a CXCL12 gradient emanating from the red pulp (119). Once in the red pulp, cells 
proliferate in extrafollicular foci and secrete low affinity IgM. In TI-1 responses, SLPCs 
up-regulate the receptor TACI and in animals lacking TACI, SLPC responses are lost (84, 
89, 110). These results suggest that TACI may be involved in the capture of pro-survival 
signals in these cells, however this has not been directly confirmed. Regardless of their 
generation, these cells persist only for a few days before their numbers involute (120).   
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Table 2.  Characteristics of Primary B Cell Subsets and their Progenitors 
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VI.  The Pim family kinases 
Recent work demonstrates a role for Pim kinases in antigen receptor signaling 
(121, 122). The Pim-1 gene encodes a serine/threonine kinase that was identified as a 
frequent target locus for Moloney Murine Leukemia Virus retroviral insertion in T cell 
lymphomas (123, 124). MMLV insertion downstream of the coding region of Pim-1 results 
in a highly stabilized mRNA, aberrant gene activation and subsequent transformation 
(124, 125). Two additional genes, Pim-2 and Pim-3, were subsequently identified by 
sequence homology. As with Pim-1, Pim-2 is also expressed in hematopoietic cells, 
whereas Pim-3 is expressed in non-hematopoietic cells (124, 126). In addition to 
promoting lymphomagenesis, Pim kinases are associated with a number of other 
pathologies, inducing polyploidy or more generalized cell cycle control defects (127-129).   
 
A.  Pim kinases and cell cycle regulation 
All three Pim kinases are members of a larger group of survival kinases whose 
constitutive expression counters pro-apoptotic signals (121). Pim kinase activity is known 
only to be regulated transcriptionally. Once expressed, the Pim kinases are constitutively 
active, as they have no known regulatory elements (121, 130). Pim-1 is involved in cell 
cycle regulation: loss of function mutations result in G1 checkpoint arrest, overexpression 
yields aberrant cycle progression with loss of growth factor requirements (131). Pim-
dependent effects on cell cycle progression operate by down-regulating the activity of 
both p21(WAF1) and p27(Kip1) (131-133). Specifically, lymphocytic turmorogenesis 
associated with the overexpression of Pim-1 is linked to its dysregulation of p21 and 
inactivation of the pro-apoptotic factor Bad (122, 134).  
Despite these apparent roles in cell cycle regulation, no major phenotypic defects 
have been reported in animals rendered deficient for Pim1, Pim-2, or both (135, 136). In 
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T cells, Pim-1 is up-regulated following stimulation or cytokine treatment and Pim kinases 
are part of one of two redundant signaling pathways required for response to CD3 and 
CD28 signals in vitro (137).  
  B.  Pim kinase signaling pathway and BLyS-mediated survival 
Recently, work by the Thompson lab and others demonstrated a role for Pim2 in 
T cell survival independent of the AKT/mTOR signaling pathway. In B cells, Pim2 was 
shown to work in parallel with the AKT/mTOR pathway to promote the survival and 
resistance to atrophy of resting cells stimulated with the obligate B cell survival factor 
BLyS (138). BlyS-mediated B cell survival in the presence of rapamycin, an AKT/mTOR 
inhibitor, was dependent on Pim2. When Pim-deficient B cells were cultured with 
rapamycin, the addition of BLyS did not improve survival, whereas Pim-sufficient B cells 
were able to utilize BLyS to improve survival. Signaling events downstream of Pim2 
facilitated the production of the anti-apoptotic protein Mcl-1 as a mechanism for 
enhanced survival. Thus, in both T cells and B cells, Pim kinases work in parallel with 
AKT/mTOR to protect cells against apoptosis. 
The process of antigen activation in vivo renders lymphocytes susceptible to 
apoptosis while markedly increasing their dependence on sustained metabolic activity. 
Because of the critical role of the Pim kinases in controlling these activities in resting and 
activated lymphocytes, we wanted to determine if they played a continuing role in the 
processes of B cell activation, proliferation and differentiation leading to antibody 
synthesis. To assess the role of Pims we employed mice with targeted mutations in the 
Pim 1 and 2 genes (Pim1-/-Pim2-/-.)   
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C.   Pim Kinases and the SLPC fate decision 
B cell biology is dominated by the function of the BCR and BLyS family 
receptors, however important these receptor molecules may be, they rely on a number of 
signaling proteins to mediate their function. Here we describe the results of the 
characterization and challenge of animals lacking two of these molecules, and how these 
results illustrate the important role of Pim kinases in various aspects of humoral 
immunity. These data support a connection between the short-lived plasma cell fate 
decision and BLyS receptor function in survival through the Pim kinase signaling 
molecules. 
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VII.   Results 
Despite earlier reports indicating a lack of severe phenotype for Pim1-/-Pim2-/- 
mice, we find severely limited serum Ig levels, indicating that a B cell phenotype exists in 
association with antibody forming cells. Pim-deficient animals also lack peritoneal B1a B 
cells as well as natural antibody. Further, these mice fail to mount SLPC responses to a 
number of immune challenges. This deficiency was found for responses to T cell 
dependent and T cell independent (type 1 or type 2) antigens. Despite the lack of an 
early SLPC response, GC reactions in the spleen following immunization with TD 
antigens were largely intact and resulted in high affinity, class switched antibody. These 
data show that Pim kinases are vital to control aspects of a normal humoral immune 
response. 
A.   Pim1-/-Pim2-/- mice have little serum Immunoglobulin 
Prior results show that Pim2 is necessary for rapamycin resistant survival of 
resting mature B cells downstream of BLyS (138).  Pim1 and 2 kinases have also been 
reported to play a role in rapamycin resistant T cell blastogenesis as well as activation 
(122).  Whether or not Pim kinases are important for the activation and maintenance of B 
cells producing a humoral response has not been investigated. Previous work 
demonstrates that animals deficient in hematopoietic Pim kinases show little or no 
impairment in their immune phenotypes. Recently evidence links these proteins to 
signaling events downstream of BLyS receptors in B cells. Given the importance of BLyS 
signaling in B cell biology, we examined the B cell phenotype of these animals more 
closely. Despite the lack of any previously reported phenotype, we found that 
immunoglobulin titers in Pim1-/-Pim2-/- mice (IgM, IgG and IgA) were significantly reduced 
(Figure 3.) 
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Figure 3: Pim1-/-Pim2-/- animals have reduced serum immunoglobulin. Serum Ig 
levels for IgM,IgG1,IgG3 and IgA were assessed by sandwich ELISA. Plates were coated 
with goat anti-mouse Ig(light chain), serum was added over a serial dilution and then 
immunoglobulin were detected using isotype-specific antibody coupled with biotin and 
extra-avidin-HRP followed by substrate. *p<0.05, **p<0.01 
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B.   Primary B cell pools develop normally in Pim1-/-Pim2-/- mice.  
To assess the impact of pim-1/2 deficiency on primary B cell pools, the 
proportions and magnitude of all splenic and bone marrow B cell populations were 
determined in normal and knockout mice. Little difference in resting populations were 
found between heterozygous control (Pim1-+/-Pim2+/-) or Pim1-/-Pim2-/- animals. BM 
precursor populations (ProB, Immature B and recirculating Mature B) were found at 
normal frequencies, while PreB cells were found to be reduced, similar to reports of Pim1-
/-Pim2-/-Pim3-/- animals (Figure 4.) Within the PreB cell compartment, large (cycling) cells 
can be further distinguished from small (non-cycling) cells by their larger, more granular 
scatter profiles. Enumeration of cells in each B cell precursor compartment reveals a 
reduction in absolute number, as well as proportion of small and large PreB cells (Figure 
5.) 
Peripheral follicular (FO), marginal zone (MZ) and transitional populations (as 
defined by Allman et al 2001(139)) were also present in proportions and absolute 
numbers similar to control animals (Figure 6.) We further examined the spleen and 
peritoneal cavity for B1 B cells and found that, splenic B1 B cells were present in normal 
frequency and numbers (Figure 7) while peritoneal B1a B cells, but not B1b B cells, were 
reduced in Pim1-+/-Pim2+/- mice (Figure 8.) We assessed anti-phosphocholine (PCh) titer 
and found that serum from Pim1-/-Pim2-/- animals contained little of none of this example 
of natural antibody (Figure 8.)  
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Figure 4: Early B cell development in Pim1-/-Pim2-/- animals shows a deficiency in 
Pre B cells. BM cells were harvested and stained to identify B cell precursor populations 
by flow cytometry. Representative FACS plots of BM B cell populations ProB 
(CD43+B220int) PreB(B220+CD43-IgM-IgD-), Immature B(B220+CD43-IgM+IgD-) and 
Mature B (B220+CD43-IgM+IgD+).  Noncycling, small PreB cells are FSC-AloSSC-Alo, 
Cycling, Large PreB cells are FSC-AmidSSC-Amid.  
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Figure 5: Absolute numbers of B cell progenitor populations in Pim1-/-2-/- animals 
confirm the Pre B cell deficiency. Absolute numbers of BM precursor populations were 
identified by FACS using counts obtained from a single hind limb of control (Pim1/2+/-) or 
Pim1-/-Pim2-/- animals. **P<0.01  
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 Figure 6: Splenic B cell subsets of Pim1-/-Pim2-/- animals show proportions and 
numbers comparable to control animals. Spleen cells were harvested, RBCs were 
lysed and remaining cells were stained with antibodies to identify peripheral B cell 
populations. Representative FACS plots of peripheral mature FO (B220+AA4.1-CD21/35int 
IgMint) MZ (B220+AA4.1-CD21/35hiIgMhi) and immature T1 (B220+AA4.1+IgM+CD23-) T2 
(B220+AA4.1+IgM+CD23+) and T3 (B200+AA4.1+IgMmid.) Total numbers (x106) of B cell 
fractions were determined from spleen counts and graphed.  
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Figure 7: Pim1-/-Pim2-/- animals have normal proportions and numbers of splenic 
B1 B cells. Splenocytes were harvested, RBCs were lysed and remaining cells were 
stained to identify splenic B1 populations. Representative FACS plots of splenic B1 B 
cells dump- (CD4-CD8-GR1-F4/80-) CD23-CD43+B220-CD5+ are shown. Total numbers 
of splenic B1s were determined from spleen counts and graphed. 
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 Figure 8: Pim1-/-Pim2-/- animals lack peritoneal B1a but not B1b B cells. The 
peritoneal cavity was lavaged and cells were stained to identify B1 B cell populations. 
Peritoneal B1 B cells (CD4-CD8-GR1-F4/80-Mac1+) were further parsed into B1a (CD23-
CD43+CD5+) and B1b (CD23-CD43+CD5-.) Enumeration of B1a and B1b B cell 
populations were determined from peritoneal cavity counts. **p<0.01 
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Figure 9: Pim1-/-Pim2-/- animals have no detectible natural antibody. Animals were 
bled and serum was purified by centrifugation. Total anti-phosphocholine antibody was 
assessed by sandwich ELISA using plates coated with Phosphocholine and detected with 
anti-Ig (Heavy and Light)-AP + substrate.	   **p<0.01 
  
C.   TI-2 responses require Pim kinases 
 An integral feature of the humoral immune response is blasting of selected 
clones following BCR binding of cognate antigen. Because of Pim kinases’ involvement in 
cell cycle, we assessed whether these animals could mount a normal immune response. 
To examine TI-2 reactions, we immunized animals intraperitoneally with NP-Ficoll and 
harvested spleens after 5 days.  Single knockouts for either Pim1 or Pim2 generated 
AFCs and displayed normal serum titers in responses to challenge (compared to Pim1+/-
Pim2+/-), while animals lacking both Pim kinases had significantly attenuated responses, 
producing minimal NP-specific antibody secreting cells AFCs and little or no NP-specific 
antibody in the sera (Figure 10-11).   
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Figure 10: Pim1-/-Pim2-/- B cells are deficient in AFC response following TI-2 
challenge. ELISpot was performed with isolated splenocytes using plates coated with 
NP33 as a capture reagent and anti-Igµ-biotin + Extravadin-AP and substrate to detect 
secreting cells. Unimmunized and immunized controls, Pim1-/-, Pim2-/- and  Pim1-/-Pim2-/- 
splenic AFCs d5 post NP-Ficoll immunization were analyzed. **p<0.01 
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Figure 11: Pim1-/-Pim2-/- B cells are deficient in generating antigen-specific 
antibody following TI-2 challenge. NP-Specific IgM ELISA was performed on serum 
from Pim1-/- and Pim2-/- single knockouts and Pim1-/-Pim2-/- double knowckouts. Splenic 
AFCs were analyzed d5 post NP-Ficoll immunization. Plates were coated with NP33 as a 
capture reagent and anti-Igµ-HRP + substrate was used for detection. **p<0.01 
 
 
In C57BL/6 animals, the NP response is dominated by BCRs expressing lambda 
light chain. It has been recently shown that the proportion of lambda+ cells are reduced in 
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similar reduction in lambda+ mature FO B cells (data not shown.)  However, to exclude 
this reduction as the basis of the TI-2 defect we immunized animals with a (T,G)AL 
peptide ficoll derivative, TG4-Ficoll, that did not favor lambda+ responding cells. We 
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that the deficiency was not specific to NP or lambda+ B cells (data not shown, produced 
by K. Willems in the Woodland laboratory, University of Massachusetts).  
Peak cellularity of TI-2 responses occurs at d4/d5 (141).To ensure that Pim 
deficient animals do not display a kinetic difference from wt animals, we assayed for 
antibody and AFCs at 3, 5, 7, and 10 days post challenge. The lack of response persists 
throughout this timeframe, indicating no kinetic explanation for the failure of response 
(Data not shown, produced by K. Willems in the Woodland laboratory, University of 
Massachusetts).  
D.   TI-1 responses require Pim kinases 
To determine whether the lack of PC generation was specific to BCR signaling, 
we extended our analysis of Pim requirements for B cell responses to TI-1 antigens. 
Pim1-/-Pim2-/- and control mice were immunized with FITC-LPS, antibody responses were 
assessed at d5 by ELISA (Data not shown, produced by K. Willems in the Woodland 
laboratory, University of Massachusetts.)  Similar to the TI-2 defect, antibody responses 
to FITC were significantly reduced in Pim1-/-Pim2-/- mice when compared to those of 
control animals. These results demonstrate that Pim-deficient animals fail to generate 
SLPC responses regardless of activation stimulus. 
Altogether, these data support a requirement for Pim kinases in mediating SLPC 
responses to T independent stimuli and that these kinases have redundant roles in 
responding cells (at least in TI-2 responses.) 
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E.   TD responses are reduced in animals lacking Pim kinases 
                         To assess the T dependent response of Pim-deficient animals, we 
immunized Pim1+/-Pim2+/- and Pim1-/-Pim2-/- mice with NP-CGG in alum. In addition to 
markers to identify cell populations, splenocytes were stained both intracellulary and 
extracellularly for lambda and NP binding in order to visualize all responding cells. At day 
7, control animals had numerous SLPCs secreting NP-specific IgM while Pim1-/-Pim2-/- 
animals had few AFCs and produced little serum antibody (Figures 12-13.)  Although 
similar to the response seen following a TI-2 immunization, the defect was not as severe.  
 
 
Figure 12. Pim1-/-Pim2-/- animals make few antigen-specific AFCs at d7 following 
immunization with NP-CGG. ELISpot were performed with isolated splenocytes using 
plates coated with NP33 as a capture reagent. Anti-Igµ-biotin + Extravadin-AP and 
substrate were used to detect secreting cells. Unimmunized and immunized controls and 
Pim1-/-Pim2-/- splenic AFCs were analyzed d7 post NP-CGG immunization. **p<0.01 
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Figure 13. Pim1-/-Pim2-/- animals make limited antigen-specific antibody at d7 
following immunization with NP-CGG. IgM ELISA was performed with serum from 
animals at d7 post NP-CGG immunization. Plates were coated with NP33 as a capture 
reagent and anti-Igµ-HRP + substrate was used for detection. **p<0.01 
To specifically address whether GCs were formed in Pim-deficient animals,  we 
examined spleen sections and splenocytes from NP-CGG-immunized animals at d10, 
during the peak of GC reactions (142).  Immunohistochemistry was performed on spleen 
sections for these animals for the presence of PNA-binding GCs located at the B cell 
follicle / PALS interface. Bright field microscopy at low magnification shows numerous 
GCs in the spleens of control and Pim1-/-Pim2-/- animals (Figure 14). High magnification 
immunofluorescence demonstrates normal organization of GC cells between CD3-
staining T cells and B220-stained B cells (Figure 15.) Flow cytometric analysis of Pim1-/-
Pim2-/- GC cells (B220+IgD-PNA+Fas+) which are also lambda+ (a surrogate marker for 
NP-specificity) are not significantly different from wt responders (Figures 16-17.) 
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Figure 14: Pim1-/-Pim2-/- animals generate germinal centers following TD challenge. 
Spleens were harvested at d10 following NP-CGG immunization and frozen in OCT 
solution under 2-methyl butane. Sections were cut at 5-8 micron thickness and fixed with 
acetone. Sections were then stained with PNA-AP followed by substrate. Bright field 
immunohistochemistry of spleen sections displays normal germinal center responses 
indicated by PNA staining regions (arrows.) 
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Figure 15: Pim1-/-Pim2-/- animals generate germinal centers with normal 
architecture following NP-CGG immunization. Spleens were harvested at d10 
following NP-CGG immunization and frozen in OCT solution under 2-methyl butane. 
Sections were cut at 5-8 micron thickness and fixed with acetone. Sections were then 
stained with antibodies (as indicated.) Immunofluorescence of spleen sections at d14 
post NP-CGG immunization display normal germinal center architecture. Spleens were 
stained with antibodies for CD3-Alexa555 (blue), IgD-FITC (green) and PNA-Rhodamine 
(red.) 
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Figure 16: Pim1-/-Pim2-/- animals generate germinal centers at d10 post NP-CGG. 
Spleens were harvested at d10 following NP-CGG immunization. Splenocytes were 
isolated as previously described and RBCs were lysed. FACS analysis identified germinal 
center cells as CD19+CD4-CD8-GR1-F4/80-fas+PNA+IgM+. NP-CGG-immunized GCs 
were further confirmed by IgD- λ+ staining. 
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Figure 17: Pim1-/-Pim2-/- animals generate germinal centers cells following NP-CGG 
immunization. Enumeration of total splenic λ+ germinal center cells at d10 post NP-
CGG were determined from absolute spleen counts and frequencies identified in figure 
16.  
 
At day 14 post immunization, SLPC numbers had reduced in the spleen of 
control and Pim deficient animals (Figure 18) reflecting a defect, rather than delay, in the 
SLPC response of Pim-deficient animals. Despite the diminished IgM response, high 
affinity, antigen-specific IgG-secreting AFCs are found in Pim1-/-Pim2-/- animals (Figure 
19.) High affinity antibody is found in the serum, but at lower concentration than control 
animals’ (Figure 20.)  
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Figure 18: Low affinity SLPC responses in Pim1-/-Pim2-/- animals peak at d7. ELISpot 
was performed for low affinity IgM-secreting AFCs at d7 and d14 post NP-CGG. 
Splenocytes were isolated and enumerated as previously indicated. Serial dilutions of 
cells were plated on NP-33-coated HTS plates and allowed to incubate undisturbed for 
four hours at physiologic temperature. Cells were then washed away and secreted 
antibody was detected using anti-IgM-biotin followed by SA-AP and substrate. Spots 
indicating antibody-forming cells were enumerated on an ELISpot reader. *p<0.05 
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Figure 19: Pim1-/-Pim2-/- animals have high affinity AFCs at d14. ELISpots were 
performed for high affinity NP-specific IgG AFCs d14 post immunization.	   Splenocytes 
were isolated and enumerated as previously indicated. Serial dilutions of cells were 
plated on NP-3-coated HTS plates and allowed to incubate undisturbed for four hours at 
physiologic temperature. Cells were then washed away and secreted antibody was 
detected using anti-IgM-biotin followed by SA-AP and substrate. Spots indicating 
antibody-forming cells were enumerated on an ELISpot reader. No significant difference 
was seen between control and Pim1-/-Pim2-/- sera. 
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Figure 20: Pim1-/-Pim2-/- animals generate high affinity, class switched antibody by 
d14. ELISA of high affinity NP-specific IgG was performed on serum from NP-CGG 
immunized aninmals at d14 following NP-CGG immunization. Antibody was detected 
using anti-IgG-biotin + extravidin-HRP and substrate. *p<0.05,**p<0.01 
 
F.   TACI is required for Pim kinase regulation by BLyS/APRIL 
 As discussed above, receptors for BLyS family survival cytokines are modulated 
following activation of naïve B cells. To assess whether differential expression of these 
receptors might be upstream of Pim kinase regulation, we assayed for Pim expression 
following APRIL or BLyS stimulation. At various timepoints, Pim1 and / or Pim2 
messages were measured in wt cells following each stimulus.  
Naïve FO B cells express BR3 and TACI. Of these two receptors, only TACI binds 
APRIL. Wt or TACI-/- B cells were co-cultured with APRIL and harvested for analysis of 
Pim1 message levels at 10, 60 and 90 minute timepoints. Message is only elevated in 
0
20
40
60
N
P
-S
pe
ci
fic
 Ig
G
 (µ
g/
m
l)
Control
Pim1-/-Pim2-/-
**
*
d14
Total High Affinity
	   52	  
response to APRIL in B cells expressing TACI (Figure 21) indicating that TACI signaling 
does positively regulate Pim1. 
To determine whether BR3, specifically, is also capable of regulating Pim 
message we stimulated cultured B cells with BLyS, which can bind either BR3 or TACI. 
By using both control cells bearing both receptors and cells from a TACI-/- animal that 
bear only BR3, we could establish whether BR3 can modulate Pim kinase message 
without TACI signals. Cells were harvested for message analysis after 12 or 18 hrs of 
culture. We find that only TACI, but not BR3, is capable of regulating Pim message 
(Figure 22.)  
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Figure 21: TACI signaling up-regulates Pim1 message in B cells. RT-PCR of Pim1 
message was performed at various timepoints following stimulation of B cells with APRIL 
in vitro. Splenocytes were harvested and CD23+ (B cells) were isolated using CD23-
biotin and MACS beads. Cells were plated in RPMI and allowed to rest prior to addition of 
1µg/ml APRIL. At the indicated time cells were harvested into lysis buffer and RNA was 
isolated. Pim1 message was assessed by qPCR. 
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Figure 22: TACI, but not BR3, signaling up-regulates Pim1 message in B cells. RT-
PCR of Pim1 message was performed at 12 or 18 hrs following stimulation of B cells with 
BLyS in vitro. Splenocytes were harvested and CD23+ (B cells) were isolated using 
CD23-biotin and MACS beads. Cells were plated in RPMI and allowed to rest prior to 
addition of 0.1µg/ml BLyS. At the indicated time cells were harvested into lysis buffer and 
RNA was isolated. Pim1 and Pim2 messages were assessed by qPCR. 
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VIII.  Discussion 
The studies described herein have investigated the roles played by Pim kinases 
in humoral immune responses.  Despite the lack of a major B cell phenotype previously 
reported in Pim1-/-Pim2-/- mice, we found that these animals display drastically reduced Ig 
titers.   To elucidate the source of this defect we pursued two avenues of investigation. 
First, we completely characterized all developing and mature primary B cell populations 
in these animals. Second, we assayed the ability of these animals to respond to various 
types of immunizations.   Our results show that despite a reduction in the pre-B cell 
compartment, the magnitude of most developing and primary B cell subsets is similar to 
wild-type controls.  However,  the Pim DKO  lack of natural antibody-secreting peritoneal 
B1a B cells, and fail to generate SLPCs in both TI and TD responses.  As a mechanism 
for this defect, we have intriguing evidence supporting a role for TACI in the regulation of 
Pim kinases required for SLPC response. Together these observations suggest a critical 
role for Pim kinases in the differentiation or survival of SLPCs.   
In characterizing Pim deficient animals, we found that most of B cell development 
is comparable to control animals with one exception. In the BM, preB cells cycle following 
successful heavy chain rearrangement resulting in increased numbers of cells relative to 
the proB cell compartment. In Pim1-/-Pim2-/- animals, this increase in preB cell numbers 
was not found. These animals have diminished proportions and numbers of small preB 
cells and have almost no large, cycling preB cells.  
Numerous studies have established the role of Pim kinases in cell cycling, often 
by a generalized mechanism of phosphorylating residues that allows binding of nuclear 
export machinery and proteosomal degredation. One such mechanism is mediated by the 
phosphorylation of the CDK inhibitor p27, leading to binding and nuclear export by 14-3-3 
and subsequent proteolysis (131, 134). Pim kinases further reinforce p27 inactivating 
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transcriptional promoters FoxO1a and FoxO3a (131). Together, these functions lead to 
CDK release and of cell cycle arrest. Pim kinases also regulate p21, which also binds cell 
cycle promoting proteins. However, when Pim kinases phosphorylate p21, this leads to 
the stabilization of nuclear p21 complexes also resulting in cell cycle progression (134). A 
third example occurs when Pim phosphorylation of PAPA-1 similarly leads to its 
degredation and release of G1 checkpoint arrest (143).  
Therefore, the reduction of cycling PreB cells may not be a surprising finding. 
This reduction may reflect an inability of Pim-deficient cells to proliferate, cell death 
resulting from failed attempt to proliferate, rapid transit through the preB cells stage or a 
number of other causes. Given prior evidence of Pim kinase involvement in cell cycle, a 
failure to proliferate seems reasonable and may be resolved using BrdU incorporation or 
other cell cycle analysis techniques. Despite this reduction, at steady-state, the defect 
does not carry forward to later developmental populations. However, this homeostatic 
compensation is a common effect found in several models of diminished B cell production 
rates such as aging or induced ablation of developing cells (144, 145). Because the rate 
of B cell development is independent of the peripheral pool and that peripheral pool size 
and lifespan is dictated by the availability of BLyS, it is likely that a proliferative defect 
may reduce the rate that mature cells are generated (146). However, the relative 
availability of BLyS will promote longevity in this pool resulting in normal steady-state cell 
numbers. It is conceivable that this proliferative defect may result in diminished diversity 
of the pre-immune pool, however, this was not investigated in the present study. 
What is remarkable is that the proliferative defect in the Pre B cell stage does not 
translate into an inability of cells to cycle following activation (at least by TD stimuli). This 
may be compensated by the presence of secondary stimuli such as CD40/CD40L 
interaction that promotes cell cycle by inducing cyclin dependent kinases and repressed 
the cell cycle inhibitor p27kip1 (147). 
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B1 B cells have been extensively studied for several decades beginning with 
their identification by Hayakawa et al as ‘Ly-1 B cells,’ however much of their biology 
remains enigmatic (148, 149). They are known to be a distinct population from 
conventional, B2, B cells, unique in their ontogeny, receptor specificity and lifespan (150). 
B1 B cells are generated early in life, but are rapidly outnumbered once follicular B cells 
are produced. It is widely accepted that B1 B cells maintain their numbers by constant, 
slow cycling and that they constitutively secrete “natural” antibodies favoring proximal 
arrangements with germline specificities. Their early generation initially suggested that 
these cells were formed only in the fetal liver, however, more recent work has established 
that B1 precursors persist in adult animals, but in low numbers (151). 
Within the B1 population there are a number of subsets that are primarily 
distinguished by their variable expression of markers such as CD5 or Mac-1. Additionally, 
B1 B cells are found both in the spleen and in coelomic cavities (e.g. peritoneum). Cells 
from each of these loci also exhibit distinctions, including in vitro survival and antibody 
production. When both cell types are isolated and grown in culture, peritoneal B1s exhibit 
extraordinary survival compared to both conventional B2 B cells and splenic B1s. 
Additionally, only B1s isolated from the peritoneal cavity constitutively produced IgM in 
culture (152). In our own laboratory, we have found that splenic and peritoneal B1 B cells 
also differ in their requirement for BLyS ligands. Specifically, splenic, but not peritoneal, 
B1 B cells are lost when animals are treated with BLyS and APRIL-sequestering soluble 
TACI-fc protein (118). Finally, B1 B cells from the spleen and peritoneal cavities are also 
distinct in their expression of the B cell differentiation factor, PU.1 (153). These data 
further show the similarity between splenic B1s and B2 B cells, while peritoneal B1 B 
cells, which do not express PU.1, may represent a completely unique lineage. 
We have found further support for the distinction between B1 subsets in that 
animals deficient for Pim kinases completely lacked peritoneal B1a B cells, but not 
splenic or peritoneal B1b B cells. Consistent with the low Ig titers and lack of B1a B cells, 
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‘natural antibody’ was completely absent. Altogether, these results suggest that 
peritoneal B1a B cells are a separate lineage of cells from other B1 B cells, and that 
these cells alone are responsible for natural antibody production. 
We did not investigate whether this lose of peritoneal B1a B cells was due to a 
developmental or survival defect. This distinction could be made by the assessment of 
neonate animals for the presence of these cells. At birth, the majority of B cells in the 
animal are B1 B cells produced in the fetal liver. One may predict that if the requirement 
for Pims is developmental, B1 B cells will be reduced from birth. Due to observations of 
reduced fetal liver size in Pim1-/-Pim2-/- animals, we favor a conclusion that B1a’s are a 
separate lineage requiring Pim kinases for their generation (C. Fox, personal 
communication.) 
An alternate explanation would be that Pim kinases are a required signaling 
molecule in some aspect of the function of AFCs in particular. This could involve the 
initiation of the plasma cell fate by regulation of transcription factors such as Pax5 or 
BLIMP-1, which could be assessed more easily with follicular B cells stimulated in vitro. 
Although, recent publication that B1 B cells do not express BLIMP-1 may require 
investigation into what transcriptional regulator controls the antibody production program 
in B1 cells (154). Because B1a B cells constitutively secrete IgM, this could contribute to 
the Ig deficiency found in Pim-deficient mice, but it does not explain the reduction in other 
isotypes. 
Further investigation of other antibody forming cells revealed a specific loss of 
SLPC generation / function following a variety of stimuli. TI and early TD responses share 
characteristics in their rapid production of extrafollilular SLPCs in the first week after 
immune challenge. Following this early response, follicular B cells engage in GC 
reactions that produce high affinity, class switched antibody. In the absence of Pim 
kinases, neither SLPCs nor the resulting low affinity antibody are generated. Because the 
defect appears downstream of both types of TI response (through the BCR in TI-2; TLRs 
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in TI-1,) and because these two types of receptors signal in very different manners, the 
requirement for Pims is unlikely to be due to signals immediately associated with the 
receptors. Rather, it is more likely to be connected with a more general feature of the 
plasma cell response or antibody generation. 
One possible explanation is that TI responses have been proposed to be 
functions of MZ and/or B1 B cells. As we have shown in our characterization, MZ B cells 
are not lacking in Pim1-/-Pim2-/- animals. Further, Tanigaki et al have shown that TI 
responses may occur even in animals lacking MZ cells (155). Using CD19-/- animals that 
specifically lack B1a B cells, Haas et al demonstrated by transfer of serum that it is the 
presence of ‘natural’ antibody, not an inability to respond to TI-2 antigens, that renders 
these animals susceptible to Streptococcus pneumoniae infection (156). This is not 
conclusive, however it does suggest that B1a B cells are not exclusively required for a TI-
2 response. This could be more accurately assessed by direct immunization of these 
CD19-/- mice with NP-Ficoll to measure the degree to which these animals generate 
appropriate AFC responses.  
However, the entire TD immune response was not defective. In Pim-deficient 
animals the SLPC is compromised, but GCs and LLPC generation appear to be largely 
normal. These data suggest that Pim kinases are specifically required for SLPC 
responses, but not subsequent AFC generation. These data support our conclusion that 
the defect is not direct ligand signaling, but a more generic defect occurring after antigen 
engagement that is specific to SLPC generation or function. 
One distinctive feature of the SLPC response is their regulation of BLyS 
receptors. The BLyS family of receptors and ligands forms a major axis in the 
homeostatic control of both pre-immune and antigen-experienced B cells.  These 
interactions are most extensively studied in the pre-immune B cell subsets, while an 
understanding of BLyS family actions in antigen-experienced subsets, including 
activated, memory, and plasma cells, is only now beginning to emerge.  These antigen-
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experienced cells display shifts in BLyS family receptor expression, suggesting they 
display different BLyS family ligand requisites than their pre-immune progenitors.  
Prior data from the lab has established that SLPCs specifically up-regulate the 
BLyS family receptor, TACI, while GC and LLPC cells use other receptors for survival 
cytokines (84, 109). Further, in PCs induced in vitro, APRIL enhances the survival of Ig 
secreting, Blimp1+,IRF+,XBP+ cells through TACI (157). In animals lacking either BLyS 
or BR3, GC reactions are limited (114, 115). Yet, even in a T-dependent stimulation, 
SLPCs in extrafollicular foci express high levels of TACI, similar to a TI response (data 
not shown, produced by R. Goenka, University of Pennsylvania.) Together with data from 
the Woodland laboratory indicating that Pim kinases are regulated by BLyS capture, and 
evidence of a SLPC defect in TACI-/- animals, we hypothesized that SLPCs use TACI to 
capture survival factors and that Pims are downstream mediators of this survival. Indeed, 
we found that TACI does regulate Pim kinases and that BR3 does not.  
In addition to survival, recent work by Grundler et al has demonstrated a 
requirement for Pim1 in proper surface expression of the chemokine receptor CXCR4 
(158). Without Pim1, surface expression of CXCR4 was diminished in BM cells resulting 
in an inability to flux Ca++ and migrate towards a CXCL12 gradient. CXCR4 – CXCL12 
interactions are involved in both BM retention of HSC as well as chemotaxis of 
plasmablasts to extrafollicular foci following stimulation (159). These data suggest that 
the coordinated expression of TACI, Pim kinases and CXCR4 are all required in the 
generation of localization and survival of extrafollicular foci in response to B cell stimuli. 
These data suggest a coordinated model where the expression of TACI is induced by 
antigenic / TLR interaction. Signaling through TACI by BLyS or APRIL then up-regulates 
CXCR4 in a Pim kinase- dependent manner. All of these players are required for the 
generation and localization / survival of extrafollicular foci in response to B cell stimuli 
(Figure 23.) Without TACI, B activated B cells receive BLyS signals only through BR3 
favoring the generation of abundant GC reactions (R. Goenka, personal communication.) 
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Without Pims, normal TACI regulation does not lead to the formation of over-abundant 
GCs, but extrafollicular SLPC responses do not occur. In animals with CXCR4-deficient B 
cells, TI responses are drastically reduced, while TD responses are comparable to 
control animals (160). 
 
Figure 23: A Model of Short-Lived Plasma Cell Response. Naïve, Follicular B cells 
are activated by encounter with antigen or TLR stimulus. TACI is up-regulated, allowing 
cells to bind BLyS or APRIL through this receptor. TACI signaling then up-regulates 
CXCR4 and down-regulated CXCR5 through a Pim kinase-dependent mechanism. 
Activated cells can then migrate towards a CXCL12 gradient emanating from the splenic 
red pulp where extrafollicular foci form.  
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The similarities between TACI-/- and Pim1-/-Pim2-/- animals’ response to 
immunization lends support to the conclusion that these signals are related. This is 
exemplified by the failure to respond to TI antigens as well as a perceived abundance of 
GCs in these animals (89, 110). Additionally, there are several reports of cell cycle 
control in TACI-/- cells that mirror findings in Pim deficient cells. Similar to our model, 
BLyS addition promotes the transition of BCR-stimulated cells to enter into cell cycle by 
antagonizing the cyclin dependent kinase inhibitor (CDKI), p18 (111). Although p18 was 
not one of the CDKIs found to be regulated by Pim kinases, this function is analogous to 
Pim kinase regulation of other CDKIs, p21 and p27 (131, 134). It remains to be 
determined whether p18 regulation by BLyS is downstream of BR3 or TACI and Pim.  
Future work will be required to address several unanswered aspects of this 
system. These include a close examination of GC B cells to determine if they show any 
cycling anomalies, and whether memory B cells are made and can be activated normally. 
The first question addresses whether Pim kinase involvement in cycling is circumvented 
in the GC. The second addresses whether there is a qualitative difference between a 
primary B cell response and a memory response, i.e. are both regulated as SLPC 
responses? Or have memory B cells bypassed all Pim requirements? 
In toto, we have shown that Pim kinases are required for proper cycling or 
survival of Pre B cells and that the generation and/or survival of activated B cell 
populations differs between SLPCs, which are Pim-dependent and GCs / LLPCs, that are 
Pim-independent. The upstream mediators of these pathways correlate with the 
expression of TACI on SLPCs and BR3 and BCMA on GCs and LLPCs, respectively. Pim 
kinases also are also required for the generation and/or survival of peritoneal B1a B cells, 
which may result from either a requirement for Pims in proper cell cycling or may reflect a 
similarity between SLPC and B1a B cell survival requirements. This combination of AFC 
abnormalities explains the observed lack of serum Ig in Pim1-/-Pim2-/- animals and 
demonstrates the role of Pim kinase function in humoral immunity.
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